Commercial insurance market projects stability as rates moderate across most lines of business
NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) — According to the latest Insurance Marketplace Realities report from WTW (Willis Towers […]
Hydrofarm Holdings Group, Inc. Announces Fireside Chat with Water Tower Research
SHOEMAKERSVILLE, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading […]
SEALSQ Getting Ready for the Arrival of Quantum Computers as Post-Quantum Cryptographic Algorithms and Semiconductors are the Front-Line of defense Against Adversarial Quantum Attacks
Geneva, Switzerland, Oct. 09, 2024 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on […]
Northrop Grumman Unveils the Next Generation of Bushmaster® Chain Gun®
PLYMOUTH, Minn., Oct. 09, 2024 (GLOBE NEWSWIRE) — Northrop Grumman Corporation (NYSE: NOC), a leading manufacturer of medium-caliber cannons, is […]
PTX Metals Appoints Dave Bell as a Technical Advisor to Its 100% Owned W2 Copper, Nickel, PGE and Gold Project
TORONTO, Oct. 09, 2024 (GLOBE NEWSWIRE) — PTX Metals Inc. (CSE: PTX) (OTCQB: PANXF, Frankfurt: 9PX) (“PTX” or the “Company”), a […]
StepStone Private Wealth Surpasses $5 Billion in AUM Milestone
NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) — StepStone Private Wealth (“SPW”) today announced it has surpassed $5 billion in […]
VCI Global Unleashes Enterprise AI Solutions with V-Gallant, Leveraging NVIDIA’s Computing Infrastructure
KUALA LUMPUR, Malaysia, Oct. 09, 2024 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (Frankfurt: H0T) (“VCI Global” or the […]
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
— Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital — BOSTON and […]
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
BERKELEY HEIGHTS, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), […]
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA- […]
